Protocol AI unveils a paradigm-shifting platform that eliminates traditional barriers between innovative ideas and functional ...

Model Context Protocol, Agent2Agent protocol, and Agent Communication Protocol take slightly different approaches to AI agent ...

Just because the various components in an advanced package work individually and together doesn't guarantee they will work ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in ... to healthcare systems. MOBILion's Melissa ...